CHRM1 and Alzheimer disease: Recent advances in marine pharmacology highlight that marine-derived fatty acids and amides can simultaneously act on acetylcholinesterase (AChE), muscarinic receptors (CHRM1), and nitric oxide synthase isoforms (NOS1/NOS2), offering a multi-target approach to combat AD pathology [8].